Related Experiment Video
Updated: Sep 17, 2025
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
Postoperative Anti-IgE Therapy for Chronic Rhinosinusitis With Nasal Polyps and Asthma: Efficacy and Prognostic
Xiaomei Yang1, Menghan Ye1,2, Minghao Pan1
1Department of Allergy, Otorhinolaryngology Hospital of the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Background:
Omalizumab has demonstrated efficacy in treating chronic rhinosinusitis (CRS) with nasal polyps and comorbid asthma (NPwAS) in preoperative settings. However, real-world evidence regarding its postoperative application remains limited. This study aimed to assess the effectiveness and safety of omalizumab in managing NPwAS following endoscopic sinus surgery (ESS), and to identify predictors for treatment response.
Methods:
This prospective observational study enrolled 60 NPwAS patients who underwent ESS between January 2020 and March 2023. Participants were divided into two groups: Control group (receiving standard care: nasal saline lavage and budesonide nasal spray) and Omalizumab group (receiving omalizumab in addition to standard care). Disease assessments, including total nasal symptom score (TNSS), visual analog scale (VAS) score, asthma control test (ACT), and sino-nasal outcome test-22 (SNOT-22), were conducted at baseline and 6 months post-treatment. Blood and nasal polyp tissue samples were collected to explore potential predictors. CRS disease control was categorized as controlled, partly controlled, or uncontrolled based on the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS).
Results:
Thirty patients in the Omalizumab group and 28 in the Control group completed the treatment and follow-up. At 6 months, CRS control was significantly better in the Omalizumab group compared to the Control group, with response rates of 40% and 14.3%, respectively (p = 0.009). The Omalizumab group also demonstrated greater mean improvements from baseline in TNSS, loss of smell score, and SNOT-22 score compared to the Control group. The treatment exhibited a favorable safety profile.
Conclusions:
Omalizumab significantly improved clinical outcomes in NPwAS patients 6 months post-surgery, underscoring its potential as an effective adjunctive therapy in the postoperative management of NPwAS.
More Related Videos
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.